Madison, Wis. — Third Wave Technologies Inc. said it has reached an agreement with Chiron Corp., Bayer Corp., and Bayer HealthCare, LLC, to dismiss Third Wave's patent lawsuit....
California clearly has the lion's share of VC investment money in the U.S. with a staggering 47 percent of all VC investment which has increased from 43 percent since 2003. The Midwest, with its ups and downs, receives, with 8 states, less than 5 percent....
Madison, Wis. — Ren-He Xu, the WiCell Institute's first employee six years ago after James Thomson made his stem-cell breakthrough, has been named director of the University of Connecticut's new human embryonic stem-cell lab....
We must pursue home-grown solutions to energy challenges including the use of corn based ethanol, biodiesel, cellulosic ethanol and other emerging “biorefining” opportunities....
It’s unclear whether Wisconsin can overcome a late start to become a leading ethanol producer, but the broader idea of using genetically engineered plants to create fuel, fiber, plastics and chemicals may be a long-term boon to the state’s rural economy....
QuatRx Pharmaceuticals Co., a pharmaceutical firm in Ann Arbor, Michigan, that licensed some of University of Wisconsin-Madison professor Hector DeLuca's technology in 2002, has filed for an IPO. ...
Most of the biotech companies you'll hear about are developing new drugs, genetic tests or similar life-science advances. But some are merging biotech with Wisconsin's old signature industries: agriculture and forest products....
It is the most important structural protein in the body, reinforcing connective tissue, bones and teeth, and forming long, fibrous cables to strengthen tendons. Now a team of scientists from the University of Wisconsin-Madison have discovered how to make it in the lab....
Madison, Wis. — Third Wave Technologies has settled with a Belgian company that sued last September over genotyping patents. Third Wave will license hepatitis C virus genotyping technology from Innogenetics, for undisclosed financial terms....
As the topic of financing is vital to a biotech company (it is priority #1, #2, and #3) and biotech companies are continually faced with the challenge of raising money due to the long product development cycle, this week's article will focus on venture capital...